Showing results (211-220 of 220) with videos related to
Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 220 results.
The Journal of Pharmacy and Pharmacology|May 10, 2002
Responsiveness, affinity constants and beta-adrenoceptor reserves for isoprenaline on aortae from normo-, pre- and hypertensive ratsYing-Yu Chen, Sheila A DoggrellExpert Opinion on Investigational Drugs|July 29, 2003
Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders?Sheila A Doggrell, Janet C WanstallCardiovascular Research|February 27, 2004
Vascular chymase: pathophysiological role and therapeutic potential of inhibitionSheila A Doggrell, Janet C WanstallExpert Opinion on Drug Safety|April 2, 2014
Gliptins - do they increase cardiovascular risk or benefit?Sheila A Doggrell, Simon B DimmittExpert Opinion on Pharmacotherapy|July 30, 2010
Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?Sheila A Doggrell, Anne-Marie ChristensenExpert Opinion on Pharmacotherapy|November 27, 2010
Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70Sheila A Doggrell, Anne-Marie ChristensenExpert Opinion on Pharmacotherapy|January 26, 2016
Sitagliptin and other 'gliptins'--why prescribe them?Sheila A Doggrell, Simon B DimmittCanadian Journal of Physiology and Pharmacology|March 26, 2005
Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitorsSheila A Doggrell, Janet C WanstallExpert Opinion on Drug Safety|October 24, 2013
Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicineSheila A Doggrell, Jules C HancoxCurrent Vascular Pharmacology|January 11, 2005
Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and plateletsJanet C Wanstall, Kerry L Homer, Sheila A DoggrellPageof 22